Vaxcyte raises $1 bln for pneumococcal vaccine development
Vaxcyte shares fell 0.3% in premarket trading after the company announced it secured $1 billion in funding through the sale of shares and convertible bonds. The funds will be used for the clinical development of its pneumococcal vaccine.